Share Twitter LinkedIn Facebook Email Katherine Clifton, MD @katherineclift4 of @WUSTL discusses actionable fusions as an anti-EGFR resistance mechanism. __________ Read here:Â https://ascopubs.org/doi/10.1200/PO.19.00141
Pashtoon Kasi MD, MS – The Role of Circulating Tumor DNA (ctDNA) in Colorectal Cancer Management – ASCO GI 2025 Colorectal 4 Mins Read
FDA Approves Sotorasib / Lumakras + Panitumumab / Vectibix for KRAS G12C Mutation Extending Survival Colorectal 3 Mins Read
NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024 Colorectal 4 Mins Read